Phase 3 readouts expected in 2030
Every Phase 3 and Phase 2/3 study on a drug AssetMemo covers whose estimated primary completion date falls in 2030, by month. The primary completion date is the sponsor's estimate of when the last participant is assessed for the primary endpoint, so it is the nearest public marker of a readout, not a confirmed date. Dates move: recent moves are on the delayed readouts page, and every phase is on the readout calendar.
Summary
266 studies (222 Phase 3, 44 Phase 2/3) across 218 drugs.
| Indication | Studies |
|---|---|
| Non-Small Cell Lung Cancer | 26 |
| Breast Cancer | 15 |
| Acute Myeloid Leukemia | 8 |
| Colorectal Cancer | 7 |
| Ovarian Cancer | 7 |
| HR+/HER2- Metastatic Breast Cancer | 6 |
| Hepatocellular Carcinoma | 5 |
| Small Cell Lung Cancer | 5 |
| Alzheimer's Disease | 4 |
| Chronic Kidney Disease | 4 |
| Crohn's Disease | 4 |
| Multiple Myeloma | 4 |
January 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-01 (month only) | Tricaprilin | Cerecin (Singapore, formerly Accera, Nestle Health Science-backed) | Alzheimer's Disease | Phase 3 | NCT05809908 |
| 2030-01 (month only) | Aficamten | Bayer, Cytokinetics, Sanofi | Hypertrophic Cardiomyopathy | Phase 2/3 | NCT06412666 |
| 2030-01 (month only) | Nivolumab, Ipilimumab, Sturlimogene erparepvec | Bristol-Myers Squibb, Ono Pharmaceutical, Replimune, Inc. | Melanoma, Uveal Melanoma | Phase 2/3 | NCT06581406 |
| 2030-01 (month only) | Atezolizumab | Chugai Pharma, Roche | Small Cell Lung Cancer | Phase 3 | NCT07625644 |
| 2030-01 (month only) | Tislelizumab | BeOne Medicines | Intrahepatic Cholangiocarcinoma (Icc) | Phase 3 | NCT07691515 |
| 2030-01-01 | Durvalumab | AstraZeneca | Endometrial Cancer | Phase 3 | NCT05255653 |
| 2030-01-01 | Naloxone (Narcan) | Emergent BioSolutions | Opioid Use Disorder | Phase 3 | NCT06089707 |
| 2030-01-01 | fingolimod (Gilenya), Ublituximab | Novartis, Tanabe Pharma Corporation, Neuraxpharm | Multiple Sclerosis | Phase 2/3 | NCT07220252 |
| 2030-01-01 | Ticagrelor | AstraZeneca | NSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI), Myocardial Infarction | Phase 3 | NCT07257198 |
| 2030-01-01 | Tafolecimab, Sintilimab, Capecitabine | Innovent Biologics, Cheplapharm Arzneimittel GmbH | Local Advanced Rectal Cancer, PD-1 Inhibitor, PCSK9 Inhibitor, RCT, Radiotherapy, Capecitabine, Oxaliplatin | Phase 3 | NCT07686796 |
| 2030-01-08 | Sotatercept | Merck & Co. | Heart Failure | Phase 3 | NCT07839585 |
| 2030-01-09 | Pelacarsen | Ionis Pharmaceuticals, Novartis | Atherosclerotic Cardiovascular Disease | Phase 3 | NCT07517263 |
| 2030-01-14 | Venglustat (GZ/SAR402671) | Sanofi | Gaucher Disease | Phase 3 | NCT07927140 |
| 2030-01-15 | Pimurutamab, HLX43 | Shanghai Henlius Biotech | Non-Small Cell Lung Cancer | Phase 2/3 | NCT07459751 |
| 2030-01-16 | Cemiplimab, Fianlimab, pemetrexed | Regeneron Pharmaceuticals, Eli Lilly | Non-Small Cell Lung Cancer | Phase 2/3 | NCT05800015 |
| 2030-01-17 | Rilvegostomig | AstraZeneca, COMPUGEN LTD | Non-Small Cell Lung Cancer | Phase 3 | NCT06868277 |
| 2030-01-18 | Pozelimab, Cemdisiran | Regeneron Pharmaceuticals, Alnylam Pharmaceuticals | Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | NCT07154745 |
| 2030-01-23 | Cenvacibart | Regeneron Pharmaceuticals | Cancer-Associated Thrombosis (CAT) | Phase 3 | NCT07410117 |
| 2030-01-24 | Nab-paclitaxel, SCTB41, pemetrexed | Bristol-Myers Squibb, Sinocelltech Group Ltd., Eli Lilly | Non-Small Cell Lung Cancer | Phase 2/3 | NCT07662395 |
| 2030-01-28 | Felzartamab | Biogen | Primary Membranous Nephropathy | Phase 3 | NCT06962800 |
| 2030-01-30 | Capecitabine | Cheplapharm Arzneimittel GmbH | Rectal Cancer | Phase 3 | NCT06205485 |
| 2030-01-31 | Nivolumab | Bristol-Myers Squibb, Ono Pharmaceutical | Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Phase 3 | NCT03811015 |
| 2030-01-31 | Pembrolizumab, pemetrexed | Merck & Co., Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT04267848 |
| 2030-01-31 | vedolizumab | Takeda Pharmaceutical Company | Pouchitis | Phase 3 | NCT06443502 |
| 2030-01-31 | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia | Phase 3 | NCT07396480 |
| 2030-01-31 | Tislelizumab | BeOne Medicines | HCC - Hepatocellular Carcinoma | Phase 3 | NCT07475026 |
February 2030
March 2030
April 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-04 (month only) | Pyrotinib | Dr. Reddy's Laboratories, HLB Life Science, Jiangsu Hengrui Pharmaceuticals | HER2-Positive Breast Cancer | Phase 3 | NCT05910398 |
| 2030-04 (month only) | upadacitinib | AbbVie | Alopecia Areata | Phase 3 | NCT06012240 |
| 2030-04 (month only) | Trastuzumab rezetecan | Glenmark Pharmaceuticals Ltd., Jiangsu Hengrui Pharmaceuticals | Breast Cancer | Phase 3 | NCT06126640 |
| 2030-04 (month only) | HRS-1780 | Jiangsu Hengrui Pharmaceuticals | Chronic Kidney Disease | Phase 3 | NCT07419828 |
| 2030-04 (month only) | Venetoclax, Azacitidine, Quizartinib | AbbVie, Roche, Bristol-Myers Squibb | Acute Myeloid Leukemia | Phase 3 | NCT07478991 |
| 2030-04 (month only) | Donanemab | Eli Lilly | Alzheimer's Disease | Phase 3 | NCT07571161 |
| 2030-04 (month only) | Afimetoran | Beeline Medicines, Bristol-Myers Squibb | Cutaneous Lupus Erythematosus (CLE), Systematic Lupus Erythematosus | Phase 2/3 | NCT07881120 |
| 2030-04-01 | Nedosiran | Novo Nordisk | Primary Hyperoxaluria Type 1 | Phase 3 | NCT04042402 |
| 2030-04-01 | Nivolumab | Bristol-Myers Squibb, Ono Pharmaceutical | Non-Small Cell Lung Cancer | Phase 3 | NCT04564157 |
| 2030-04-01 | Bevacizumab | Roche | Colorectal Cancer | Phase 3 | NCT05797467 |
| 2030-04-01 | Sintilimab | Innovent Biologics | Nasopharyngeal Carcinoma (NPC) | Phase 3 | NCT07459296 |
| 2030-04-01 | Venetoclax | AbbVie, Roche | Acute Myeloid Leukemia | Phase 3 | NCT07539818 |
| 2030-04-02 | Tarlatamab | Amgen | Small Cell Lung Cancer | Phase 3 | NCT06211036 |
| 2030-04-02 | Votoplam | Novartis | Huntington's Disease | Phase 3 | NCT07326709 |
| 2030-04-05 | Pembrolizumab, Pembrolizumab berahyaluronidase alfa, Zanzalintinib | Merck & Co., Exelixis | Colorectal Cancer | Phase 3 | NCT07750158 |
| 2030-04-15 | bimekizumab | UCB | Psoriasis | Phase 3 | NCT07836283 |
| 2030-04-17 | Volrustomig | AstraZeneca | Head and Neck Squamous Cell Carcinoma | Phase 3 | NCT06129864 |
| 2030-04-18 | zasocitinib | Takeda Pharmaceutical Company | Psoriatic Arthritis | Phase 3 | NCT07871721 |
| 2030-04-20 | Tarlatamab | Amgen | Small Cell Lung Cancer | Phase 3 | NCT06117774 |
| 2030-04-22 | Methotrexate, Dexamethasone | Lymphoblastic Lymphoma, Childhood | Phase 3 | NCT04043494 | |
| 2030-04-24 | Pembrolizumab, Trastuzumab Deruxtecan | Merck & Co., AstraZeneca, Daiichi Sankyo | Non-Small Cell Lung Cancer | Phase 3 | NCT06899126 |
| 2030-04-30 | Imlifidase | Hansa Biopharma | Long Term Efficacy and Safety | Phase 3 | NCT05937750 |
| 2030-04-30 | Modafinil | Apotex Inc. | Cognition, Healthy Participants | Phase 3 | NCT07231497 |
| 2030-04-30 | Modafinil | Apotex Inc. | Psychosis, Schizophrenia Disorder, Schizoaffective Disorder, Major Depressive Disorder With Psychotic Features, Bipolar Disorder With Psychotic Features, Psychosis NOS, Schizophreniform Disorder, Psychotic Disorder, Cognition | Phase 3 | NCT07263022 |
| 2030-04-30 | Futibatinib (Lytgobi) | Taiho Pharmaceutical | Biliary Tract Cancer | Phase 3 | NCT07710885 |
| 2030-04-30 | RC148 | AbbVie, RemeGen Co., Ltd. | Advanced Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2/3 | NCT07935369 |
May 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-05 (month only) | Ivonescimab, Ligufalimab | Akeso, Summit Therapeutics | Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) | Phase 3 | NCT07264075 |
| 2030-05 (month only) | Gamgertamig (CM336), Lumrotatug | Gilead Sciences, Keymed Biosciences, Lakefront Biotherapeutics NV | Multiple Myeloma | Phase 3 | NCT07910903 |
| 2030-05-01 | Capecitabine | Cheplapharm Arzneimittel GmbH | Nasopharyngeal Carcinoma (NPC) | Phase 3 | NCT06900218 |
| 2030-05-01 | Bevacizumab, Fluzoparib | Roche, Jiangsu Hengrui Pharmaceuticals | Ovarian Cancer | Phase 3 | NCT06954584 |
| 2030-05-03 | Cemiplimab | Regeneron Pharmaceuticals | Cutaneous Squamous Cell Carcinoma (CSCC) | Phase 3 | NCT06585410 |
| 2030-05-15 | Dapagliflozin | AstraZeneca, Ono Pharmaceutical | Polycystic Kidney, Autosomal Dominant | Phase 3 | NCT07280585 |
| 2030-05-18 | Pembrolizumab, Sacituzumab Tirumotecan | Merck & Co., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Breast Cancer | Phase 3 | NCT06841354 |
| 2030-05-21 | Bevacizumab, GSK 5733584 | Roche, GlaxoSmithKline | Ovarian Cancer | Phase 3 | NCT07684612 |
| 2030-05-28 | Nucresiran | Alnylam Pharmaceuticals | Transthyretin Amyloidosis with Cardiomyopathy | Phase 3 | NCT07052903 |
| 2030-05-29 | Ribociclib | Novartis | Breast Cancer | Phase 3 | NCT03701334 |
| 2030-05-30 | Sintilimab, Bevacizumab | Innovent Biologics, Roche | Hepatocellular Carcinoma | Phase 3 | NCT07594340 |
| 2030-05-31 | Rituximab | Biogen, Chugai Pharma, Roche | Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications | Phase 3 | NCT03394365 |
| 2030-05-31 | afimkibart | Pfizer, Roche | Crohn's Disease | Phase 3 | NCT07298421 |
| 2030-05-31 | Atezolizumab, Nivolumab, Cabozantinib, Zanzalintinib | Chugai Pharma, Roche, Bristol-Myers Squibb | Hepatocellular Carcinoma, Colorectal Cancer, Renal Cell Carcinoma, Prostate Cancer | Phase 3 | NCT07620574 |
| 2030-05-31 | Adebrelimab, pemetrexed | Jiangsu Hengrui Pharmaceuticals, Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT07822542 |
June 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-06 (month only) | Lecanemab | Biogen, Eisai | Alzheimer's Disease | Phase 3 | NCT06384573 |
| 2030-06 (month only) | Methylprednisolone | Pfizer | Rejection | Phase 3 | NCT06474273 |
| 2030-06 (month only) | Olaparib | AstraZeneca, Merck & Co. | Endometrial Cancer, p53abn | Phase 3 | NCT06712472 |
| 2030-06 (month only) | Alixorexton | Alkermes plc | Narcolepsy, Idiopathic Hypersomnia | Phase 2/3 | NCT06767683 |
| 2030-06 (month only) | Venetoclax | AbbVie, Roche | Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma | Phase 2/3 | NCT06855810 |
| 2030-06 (month only) | bleximenib | Johnson & Johnson | Acute Myeloid Leukemia | Phase 3 | NCT07223814 |
| 2030-06 (month only) | SHR-1501 | Jiangsu Hengrui Pharmaceuticals | NMIBC | Phase 3 | NCT07424287 |
| 2030-06 (month only) | BEBT-209 | BeBetter Med | Breast Cancer | Phase 2/3 | NCT07544056 |
| 2030-06 (month only) | DR10624 | Zhejiang Doer Biologics | Severe Hypertriglyceridemia | Phase 3 | NCT07680829 |
| 2030-06-01 | sildenafil | Pfizer, Viatris | Cancer | Phase 2/3 | NCT06800092 |
| 2030-06-01 | Trastuzumab rezetecan | Glenmark Pharmaceuticals Ltd., Jiangsu Hengrui Pharmaceuticals | Ovarian Cancer | Phase 3 | NCT06990503 |
| 2030-06-01 | Donanemab, Nivegacetor | Eli Lilly, Roche | Alzheimer's Disease | Phase 2/3 | NCT06996730 |
| 2030-06-10 | Surovatamig | AstraZeneca | Large B-Cell Lymphoma | Phase 3 | NCT07215585 |
| 2030-06-14 | PF-08634404, Tarlatamab | Pfizer, Shenyang Sunshine Pharmaceutical, Amgen | Small Cell Lung Cancer | Phase 2/3 | NCT07226999 |
| 2030-06-15 | Cadonilimab | Akeso | Resectable Colon Cancer, MSI-H/dMMR Colorectal Cancer | Phase 3 | NCT07412613 |
| 2030-06-16 | Utidelone, Capecitabine | Beijing Biostar Pharmaceuticals, Cheplapharm Arzneimittel GmbH | Breast Cancer, TNBC | Phase 3 | NCT07021261 |
| 2030-06-25 | Intismeran Autogene | Merck & Co., Moderna | Non-Small Cell Lung Cancer | Phase 3 | NCT06077760 |
| 2030-06-26 | Quizartinib | Daiichi Sankyo, Innovent Biologics | Acute Myeloid Leukemia | Phase 3 | NCT06578247 |
| 2030-06-26 | PF-06651600 | Pfizer | Severe Alopecia Areata | Phase 3 | NCT07029828 |
| 2030-06-28 | Iptacopan | Novartis | IgA Nephropathy | Phase 3 | NCT06994845 |
| 2030-06-28 | Torvutatug samrotecan | AstraZeneca | Ovarian Cancer | Phase 3 | NCT07851025 |
| 2030-06-30 | Vanzacaftor / tezacaftor / deutivacaftor | Vertex Pharmaceuticals | Cystic Fibrosis | Phase 3 | NCT05422222 |
| 2030-06-30 | Methotrexate | Mature B-cell Non-Hodgkin Lymphoma | Phase 2/3 | NCT07168980 | |
| 2030-06-30 | Thalidomide, Capecitabine | Bristol-Myers Squibb, Cheplapharm Arzneimittel GmbH | Hepatocellular Carcinoma | Phase 2/3 | NCT07309419 |
| 2030-06-30 | Setidegrasib | Astellas Pharma | Non-Small Cell Lung Cancer | Phase 3 | NCT07566052 |
| 2030-06-30 | Toripalimab, Disitamab Vedotin | Coherus BioSciences, Inc., Shanghai Junshi Bioscience, Pfizer | Urinary Bladder Neoplasms | Phase 2/3 | NCT07608224 |
| 2030-06-30 | Imatinib mesylate prodrug (IkT-001Pro) | Inhibikase Therapeutics | Pulmonary Arterial Hypertension | Phase 3 | NCT07632898 |
| 2030-06-30 | GFH375 | GenFleet Therapeutics, Verastem, Inc. | Non-Small Cell Lung Cancer | Phase 3 | NCT07668752 |
July 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-07 (month only) | Belinostat | Acrotech Biopharma | Peripheral T-Cell Lymphoma | Phase 3 | NCT06072131 |
| 2030-07 (month only) | Bictegravir/lenacapavir (Bixlenvo) | Gilead Sciences | HIV | Phase 2/3 | NCT06532656 |
| 2030-07 (month only) | autologous cultured chondrocytes on porcine collagen membrane | Vericel Corporation | Chondral Defect, Articular Cartilage Defect | Phase 3 | NCT06915233 |
| 2030-07 (month only) | Avacopan | Amgen, Vifor Pharma | Granulomatosis With Polyangiitis, Wegener' | Phase 2/3 | NCT07176546 |
| 2030-07 (month only) | Obinutuzumab, Lenalidomide | Roche, Bristol-Myers Squibb, Celgene Corporation | Follicular Lymphoma | Phase 3 | NCT07719855 |
| 2030-07-01 | Capecitabine | Cheplapharm Arzneimittel GmbH | Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8, Locally Advanced Rectal Adenocarcinoma | Phase 2/3 | NCT05610163 |
| 2030-07-01 | Nab-paclitaxel, Rilvegostomig | Bristol-Myers Squibb, AstraZeneca, COMPUGEN LTD | Non-Small Cell Lung Cancer | Phase 3 | NCT06692738 |
| 2030-07-01 | Dapagliflozin, Balcinrenone | AstraZeneca, Ono Pharmaceutical | Chronic Kidney Disease | Phase 3 | NCT07624305 |
| 2030-07-04 | Trastuzumab Deruxtecan, Pertuzumab, Palbociclib | AstraZeneca, Daiichi Sankyo, Roche | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT07683754 |
| 2030-07-08 | Brivaracetam | UCB | Epilepsy | Phase 3 | NCT04715646 |
| 2030-07-08 | garetosmab | Regeneron Pharmaceuticals | Fibrodysplasia Ossificans Progressiva | Phase 3 | NCT07559513 |
| 2030-07-11 | Cliramitug | AstraZeneca | Transthyretin Amyloidosis with Cardiomyopathy | Phase 3 | NCT07789483 |
| 2030-07-22 | GSK 5733584 | GlaxoSmithKline | Ovarian Cancer | Phase 3 | NCT07286266 |
| 2030-07-28 | petrelintide | Roche, Zealand Pharma | Obesity | Phase 3 | NCT07843472 |
| 2030-07-29 | PF-06823859 | Pfizer | Dermatomyositis | Phase 3 | NCT05895786 |
| 2030-07-29 | Daratumumab, Bortezomib, Dexamethasone | Johnson & Johnson, Janssen, Takeda Pharmaceutical Company | AL Amyloidosis | Phase 3 | NCT06022939 |
| 2030-07-30 | Nivolumab, Relatlimab, pemetrexed | Bristol-Myers Squibb, Ono Pharmaceutical, Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT06561386 |
| 2030-07-30 | Semaglutide (Ozempic) | Novo Nordisk | Schizophrenia Disorder, Metabolic Syndrome, Antipsychotic-induced Weight Gain, Cardiovascular Risk, Insulin Resistance | Phase 3 | NCT07770282 |
| 2030-07-31 | Rimegepant (Nurtec ODT) | Eisai, Pfizer | Migraine | Phase 3 | NCT04743141 |
| 2030-07-31 | Goserelin, Docetaxel | AstraZeneca, TerSera Therapeutics LLC, Sanofi | Prostate Cancer | Phase 2/3 | NCT06282588 |
| 2030-07-31 | baricitinib, N-acetylcysteine, Dexamethasone | Eli Lilly, Incyte, Apotex Inc. | Dengue, Severe Dengue, Mosquito-Borne Diseases, Vector Borne Diseases, Arbovirus Infections, Flavivirus Infections, RNA Virus Infections, Hemorrhagic Fever | Phase 3 | NCT07543458 |
August 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-08 (month only) | Seladelpar | Gilead Sciences, Kaken Pharmaceutical | Primary Biliary Cholangitis | Phase 3 | NCT06051617 |
| 2030-08 (month only) | Stiripentol | Biocodex | Primary Hyperoxaluria Type 1 | Phase 3 | NCT06465472 |
| 2030-08 (month only) | Tirzepatide (Mounjaro), retatrutide | Eli Lilly, Tanabe Pharma Corporation | Metabolic Dysfunction-Associated Steatotic Liver Disease | Phase 3 | NCT07165028 |
| 2030-08 (month only) | Pitolisant (Wakix) | Bioprojet, Harmony Biosciences, Viatris | Prader-Willi Syndrome | Phase 3 | NCT07219485 |
| 2030-08 (month only) | Olezarsen | Ionis Pharmaceuticals, Swedish Orphan Biovitrum AB (publ), Theratechnologies | Familial Chylomicronemia Syndrome | Phase 3 | NCT07727538 |
| 2030-08-01 | Denosumab (Prolia) | Amgen, Daiichi Sankyo | Charcot Foot, Diabetes Mellitus | Phase 3 | NCT04547348 |
| 2030-08-01 | Axitinib intravitreal implant (OTX-TKI) | OCULAR THERAPEUTIX, INC | Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration | Phase 3 | NCT07516132 |
| 2030-08-01 | Cadonilimab | Akeso | Colon Rectal Cancer Adenocarcinoma, Peritoneal (Metastatic) Cancer, Second-line Treatment, Radiation Therapy, Immunotherapy | Phase 3 | NCT07815834 |
| 2030-08-10 | Azacitidine, Lisaftoclax | Bristol-Myers Squibb, Ascentage Pharma Group Inc. | Acute Myeloid Leukemia | Phase 3 | NCT07686965 |
| 2030-08-12 | vedolizumab | Takeda Pharmaceutical Company | Ulcerative Colitis, Crohn's Disease | Phase 3 | NCT06405087 |
| 2030-08-30 | Taletrectinib | Eisai, Innovent Biologics, Nippon Kayaku | Non-Small Cell Lung Cancer | Phase 3 | NCT07154706 |
| 2030-08-31 | Nab-paclitaxel, Gemcitabine | Bristol-Myers Squibb, Eli Lilly | Pancreatic Cancer | Phase 3 | NCT07155629 |
September 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-09 (month only) | Brexpiprazole (Rexulti) | H. Lundbeck, Otsuka Holdings | Bipolar Depression | Phase 3 | NCT04569448 |
| 2030-09 (month only) | Brentuximab Vedotin | Pfizer, Seagen, Takeda Pharmaceutical Company | Hodgkin Lymphoma | Phase 3 | NCT04685616 |
| 2030-09 (month only) | Pembrolizumab, Nivolumab | Merck & Co., Bristol-Myers Squibb, Ono Pharmaceutical | Melanoma | Phase 3 | NCT06488482 |
| 2030-09 (month only) | Empagliflozin | Boehringer Ingelheim, Eli Lilly | Kidney Stone, Nephrolithiasis, Dietary Exposure | Phase 3 | NCT06653738 |
| 2030-09 (month only) | Venetoclax, Azacitidine | AbbVie, Roche, Bristol-Myers Squibb | Acute Myeloid Leukemia | Phase 3 | NCT07082452 |
| 2030-09 (month only) | Osimertinib, Telisotuzumab Adizutecan | AstraZeneca, AbbVie | Non-Small Cell Lung Cancer | Phase 2/3 | NCT07155187 |
| 2030-09 (month only) | Everolimus | Novartis | Cowden's Disease, Cowden's Syndrome, Lhermitte-Duclos Disease, Cerebellum Dysplastic Gangliocytoma, Bannayan Zonana Syndrome, Myhre Riley Smith Syndrome, Riley Smith Syndrome, PTEN Hamartoma Tumor Syndrome, Bannayan Riley Ruvalcaba Syndrome | Phase 2/3 | NCT07218575 |
| 2030-09 (month only) | ABBV-706 | AbbVie | Small Cell Lung Cancer | Phase 3 | NCT07365241 |
| 2030-09 (month only) | Roxadustat | Astellas Pharma, AstraZeneca, Kyntra Bio | Myelodysplastic Syndromes | Phase 3 | NCT07722988 |
| 2030-09-01 | Utidelone, Capecitabine | Beijing Biostar Pharmaceuticals, Cheplapharm Arzneimittel GmbH | Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2/3 | NCT06841679 |
| 2030-09-01 | Semaglutide (Wegovy) | Novo Nordisk | Aortic Stenosis, Heart Failure | Phase 3 | NCT07090343 |
| 2030-09-01 | Semaglutide (Wegovy) | Novo Nordisk | Gestational Diabetes Mellitus (GDM), Metabolic Syndrome | Phase 2/3 | NCT07797036 |
| 2030-09-02 | Nivolumab, Relatlimab | Bristol-Myers Squibb, Ono Pharmaceutical | Urothelial Carcinoma | Phase 2/3 | NCT05987241 |
| 2030-09-02 | Rituximab, Surovatamig | Biogen, Chugai Pharma, Roche | Large B-Cell Lymphoma | Phase 3 | NCT07911553 |
| 2030-09-04 | Daratumumab, Ramantamig | Johnson & Johnson | Multiple Myeloma | Phase 3 | NCT07665450 |
| 2030-09-11 | Datopotamab Deruxtecan, Rilvegostomig | AstraZeneca, Daiichi Sankyo, COMPUGEN LTD | Urothelial Carcinoma | Phase 3 | NCT07720284 |
| 2030-09-16 | zenagamtide | Novo Nordisk | Obesity | Phase 3 | NCT07861100 |
| 2030-09-18 | Pumitamig | BioNTech, Bristol-Myers Squibb | Non-Small Cell Lung Cancer | Phase 3 | NCT07361497 |
| 2030-09-20 | Deulumateperone | Intra-Cellular Therapies, Johnson & Johnson | Generalized Anxiety Disorder | Phase 3 | NCT07856420 |
| 2030-09-22 | Trigel | STADA Arzneimittel | Parkinson's Disease | Phase 3 | NCT07151378 |
| 2030-09-23 | Zilebesiran | Alnylam Pharmaceuticals, Roche | Hypertension | Phase 3 | NCT07181109 |
| 2030-09-23 | Depemokimab | GlaxoSmithKline | Asthma | Phase 3 | NCT07456033 |
| 2030-09-30 | Lorlatinib, Sargramostim, Dinutuximab | Pfizer, Partner Therapeutics, Inc., United Therapeutics | Neuroblastoma | Phase 3 | NCT03126916 |
| 2030-09-30 | Nivolumab | Bristol-Myers Squibb, Ono Pharmaceutical | Melanoma | Phase 3 | NCT06264180 |
| 2030-09-30 | Cabozantinib | Exelixis, Ipsen, Takeda Pharmaceutical Company | Refractory Differentiated Thyroid Gland Carcinoma | Phase 3 | NCT06475989 |
| 2030-09-30 | Dexamethasone | Tick-Borne Encephalitis | Phase 3 | NCT07584525 |
October 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-10 (month only) | Abemaciclib | Eli Lilly | HR+/HER2- Metastatic Breast Cancer, Breast Cancer | Phase 3 | NCT04584853 |
| 2030-10 (month only) | Delpacibart etedesiran | Novartis | Myotonic Dystrophy Type 1 | Phase 3 | NCT07008469 |
| 2030-10 (month only) | Darovasertib | IDEAYA Biosciences, Servier | Uveal Melanoma | Phase 3 | NCT07015190 |
| 2030-10 (month only) | Adebrelimab, Trastuzumab rezetecan | Jiangsu Hengrui Pharmaceuticals, Glenmark Pharmaceuticals Ltd. | Patients With Unresectable Locally Advanced or Metastatic Untreated Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 3 | NCT07118527 |
| 2030-10 (month only) | Cetuximab | Eli Lilly, Merck KGaA | Metastatic Colorectal Cancer | Phase 3 | NCT07389265 |
| 2030-10 (month only) | Lenacapavir (Sunlenca), Tenofovir alafenamide/emtricitabine | Gilead Sciences | HIV | Phase 2/3 | NCT07708727 |
| 2030-10-04 | elecoglipron | AstraZeneca, Eccogene | Chronic Kidney Disease | Phase 3 | NCT07753993 |
| 2030-10-14 | Lenalidomide, Isatuximab, Methylprednisolone, Dexamethasone | Bristol-Myers Squibb, Celgene Corporation, Sanofi | Multiple Myeloma | Phase 3 | NCT04270409 |
| 2030-10-15 | Temozolomide | Merck & Co. | Glioblastoma | Phase 2/3 | NCT07873996 |
| 2030-10-16 | Efimosfermin alfa | GlaxoSmithKline | MASH / NASH | Phase 3 | NCT07704892 |
| 2030-10-18 | Daratumumab, Lenalidomide, Elranatamab | Johnson & Johnson, Bristol-Myers Squibb, Celgene Corporation | Multiple Myeloma | Phase 3 | NCT05623020 |
| 2030-10-21 | Capecitabine | Cheplapharm Arzneimittel GmbH | Pancreatic Cancer | Phase 3 | NCT06958328 |
| 2030-10-22 | Pacibekitug | Novartis | Myocardial Infarction | Phase 3 | NCT07938411 |
| 2030-10-24 | tilrekimig | Pfizer | Chronic Obstructive Pulmonary Disease | Phase 2/3 | NCT07363694 |
| 2030-10-30 | metformin | Acute Ischemic Stroke | Phase 3 | NCT07899307 | |
| 2030-10-31 | phentermine/topiramate | VIVUS | Healthy Volunteers | Phase 3 | NCT06905626 |
| 2030-10-31 | deucravacitinib | Bristol-Myers Squibb | Psoriatic Arthritis, Psoriasis, Systemic Lupus Erythematosus, Sjögren's Disease | Phase 3 | NCT07791199 |
| 2030-10-31 | Ivonescimab, Enfortumab Vedotin | Akeso, Summit Therapeutics, Astellas Pharma | Metastatic Urothelial Carcinoma, Metastatic Urothelial Carcinoma (UC) | Phase 2/3 | NCT07815665 |
November 2030
| Primary completion | Drug | Developer | Indication | Phase | Study |
|---|---|---|---|---|---|
| 2030-11 (month only) | Temozolomide | Merck & Co. | Glioblastoma | Phase 2/3 | NCT05685004 |
| 2030-11-01 | Semaglutide (Wegovy) | Novo Nordisk | Obesity | Phase 3 | NCT06934655 |
| 2030-11-05 | Dostarlimab | GlaxoSmithKline | Endometrial Cancer | Phase 3 | NCT07860450 |
| 2030-11-08 | Pumitamig | BioNTech, Bristol-Myers Squibb | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma | Phase 2/3 | NCT07221149 |
| 2030-11-18 | Rilvegostomig, pemetrexed | AstraZeneca, COMPUGEN LTD, Eli Lilly | Non-Small Cell Lung Cancer | Phase 3 | NCT06627647 |
| 2030-11-25 | Mesutoclax | Beijing InnoCare Pharma Tech Co. | Chronic Lymphocytic Leukemia | Phase 2/3 | NCT06378138 |
| 2030-11-27 | Zanzalintinib | Exelixis | Renal Cell Carcinoma | Phase 3 | NCT07489495 |
| 2030-11-30 | Quemliclustat | Arcus Biosciences, Gilead Sciences, Taiho Pharmaceutical | Pancreatic Ductal Adenocarcinoma | Phase 3 | NCT06608927 |
| 2030-11-30 | Fruquintinib | HUTCHMED, Takeda Pharmaceutical Company | Metastatic Oesogastric Adenocarcinoma | Phase 3 | NCT07270991 |
| 2030-11-30 | Adebrelimab, Gemcitabine, HRS-4642 | Jiangsu Hengrui Pharmaceuticals, Eli Lilly | Pancreatic Cancer | Phase 3 | NCT07900789 |
December 2030
Source: ClinicalTrials.gov, each study's record, checked daily. Studies that are terminated, withdrawn or completed are left out, as are programmes their developer has stopped. A month-only date is shown as given.